GlaxoSmithKline PLC


[email protected]

GlaxoSmithKline PLC (a U.K. company) disclosed that, while it “does not have a legal entity based in Iran . . . it does export certain pharmaceutical and vaccine products to Iran, via sales by non-U.S. entities, to two privately held Iranian distributors.” GSK stated that it has “no direct knowledge of the identity of its distributors’ downstream customers in Iran, and it is possible that these customers include entities, such as government-owned hospitals and pharmacies that are owned or controlled directly or indirectly by the Iranian government.” Jahan Behbood lists itself as an agent for GlaxoSmithKline. (January 2018)


GlaxoSmithKline PLC has a U.S. Website


GlaxoSmithKline LLC and GlaxoSmithKline (Holdings) are subsidaries of GlaxoSmithKline PLC


"While Western powers have identified a small group of sectors for Iranian sanction relief, a much wider set of European and U.S. companies—from pharmaceutical firms and medical-equipment makers to food companies and traders—also stands to regain lost Iranian trade as soon as relief measures are formally adopted next month. Western governments singled out Iran's automotive and aviation sectors for temporary sanction relief, while allowing petrochemical exports and trade in gold and other precious metals. But the fine print of the deal also clears the way for GlaxoSmithKline PLC and Sanofi SA, for example, to restart selling many of the drugs they had been forced to cut back on because of increasingly stiff financial sanctions…Pharmaceutical companies Glaxo and AstraZeneca PLC of the U.K. and Sanofi of France reported annual Iranian sales of roughly $32.2 million, $14 million and $13.9 million, respectively, according to their annual SEC reports. A spokeswoman for Glaxo said 'things are moving at the moment' with the proposed sanctions relief and that the company is 'monitoring the situation, but it's early days.'" (Wall Street Journal, "Iran Deal Opens Door for Businesses," 12/1/13)